Time to castration resistance is an independent predictor of castration-resistant prostate cancer survival - Abstract

Department of Clinical Therapeutics, The University of Athens, 80 Vasilissis Sofias Ave, 11528, Athens, Greece.

 

Easily assessable clinical predictors of response to chemotherapy in advanced castration-resistant prostate cancer (CRPC) are few. The objective of this retrospective study was to search for and identify such candidate predictors of outcome.

A retrospective analysis of clinical data of CRPC patients entered in the Clinical Therapeutics' departmental prostate cancer database from 1996-2009 was performed. Univariate and multivariate analyses for progression-free survival and overall survival included patients receiving both docetaxel- and non-docetaxel-containing regimens.

From 1996 until June 2009, 286 out of 313 patients in our database were treated with chemotherapy. Prostate-specific antigen (PSA) reduction >30% correlated with improved survival irrespective of treatment. Beyond previously reported predictors, i.e. baseline PSA >30 ng/dl, hemoglobin below 10 mg/dl, weight loss, poor performance status, elevated lactic dehydrogenase and alkaline phosphatase, and time to CRPC of less than or equal to two years was associated with a poor overall survival and shorter progression-free survival upon univariate analysis. Pain was associated with shorter survival. Multivariate analysis confirmed time to CRPC, lactate dehydrogenase and alkaline phosphatase as independent predictors of overall and progression-free survival.

Time to castration resistance is an important predictor of outcome in CRPC. PSA reduction >30% predicts survival improvement following chemotherapy for CRPC regardless of chemotherapy applied.

Written by:
Bournakis E, Efstathiou E, Varkaris A, Wen S, Chrisofos M, Deliveliotis C, Alamanis C, Anastasiou I, Constantinides C, Bamias A, Dimopoulos MA.   Are you the author?

Reference: Anticancer Res. 2011 Apr;31(4):1475-82.

PubMed Abstract
PMID: 21508406

UroToday.com Prostate Cancer Section

 

 

email news signup